Jane Street Group LLC Sells 38,269 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Jane Street Group LLC trimmed its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 33.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,641 shares of the company’s stock after selling 38,269 shares during the period. Jane Street Group LLC’s holdings in GoodRx were worth $539,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. American Century Companies Inc. acquired a new stake in GoodRx during the second quarter valued at approximately $18,183,000. Point72 Asset Management L.P. acquired a new position in shares of GoodRx in the 3rd quarter worth approximately $11,295,000. Rubric Capital Management LP boosted its holdings in shares of GoodRx by 76.5% in the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after acquiring an additional 1,619,748 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of GoodRx by 36.5% in the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after acquiring an additional 1,102,758 shares in the last quarter. Finally, Raymond James & Associates boosted its holdings in shares of GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock worth $2,734,000 after acquiring an additional 267,951 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors.

GoodRx Price Performance

GDRX opened at $4.45 on Monday. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The company has a fifty day simple moving average of $4.90 and a 200 day simple moving average of $6.67. The stock has a market cap of $1.70 billion, a P/E ratio of -148.33, a P/E/G ratio of 3.43 and a beta of 1.29.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Barclays reduced their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Mizuho assumed coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Citigroup reduced their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Finally, Morgan Stanley reduced their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.64.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.